Literature DB >> 12960311

Activating and inhibitory Ly49 receptors modulate NK cell chemotaxis to CXC chemokine ligand (CXCL) 10 and CXCL12.

Marit Inngjerdingen1, Bent Rolstad, James C Ryan.   

Abstract

NK cells can migrate into sites of inflammatory responses or malignancies in response to chemokines. Target killing by rodent NK cells is restricted by opposing signals from inhibitory and activating Ly49 receptors. The rat NK leukemic cell line RNK16 constitutively expresses functional receptors for the inflammatory chemokine CXC chemokine ligand (CXCL)10 (CXCR3) and the homeostatic chemokine CXCL12 (CXCR4). RNK-16 cells transfected with either the activating Ly49D receptor or the inhibitory Ly49A receptor were used to examine the effects of NK receptor ligation on CXCL10- and CXCL12-mediated chemotaxis. Ligation of Ly49A, either with Abs or its MHC class I ligand H2-D(d), led to a decrease in chemotactic responses to either CXCL10 or CXCL12. In contrast, Ly49D ligation with Abs or H2-D(d) led to an increase in migration toward CXCL10, but a decrease in chemotaxis toward CXCL12. Ly49-dependent effects on RNK-16 chemotaxis were not the result of surface modulation of CXCR3 or CXCR4 as demonstrated by flow cytometry. A mutation of the Src homology phosphatase-1 binding motif in Ly49A completely abrogated Ly49-dependent effects on both CXCL10 and CXCL12 chemotaxis, suggesting a role for Src homology phosphatase-1 in Ly49A/chemokine receptor cross-talk. Ly49D-transfected cells were pretreated with the Syk kinase inhibitor Piceatannol before ligation, which abrogated the previously observed changes in migration toward CXCL10 and CXCL12. Piceatannol also abrogated Ly49A-dependent inhibition of chemotaxis toward CXCL10, but not CXCL12. Collectively, these data suggest that Ly49 receptors can influence NK cell chemotaxis within sites of inflammation or tumor growth upon interaction with target cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960311     DOI: 10.4049/jimmunol.171.6.2889

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

1.  Expression of regulator of G protein signalling proteins in natural killer cells, and their modulation by Ly49A and Ly49D.

Authors:  Lise Kveberg; James C Ryan; Bent Rolstad; Marit Inngjerdingen
Journal:  Immunology       Date:  2005-07       Impact factor: 7.397

2.  PGI2 Controls Pulmonary NK Cells That Prevent Airway Sensitization to House Dust Mite Allergen.

Authors:  Bryan Simons; Maria E Ferrini; Sophia Carvalho; David J P Bassett; Zeina Jaffar; Kevan Roberts
Journal:  J Immunol       Date:  2016-11-28       Impact factor: 5.422

3.  NKp30 is a functional activation receptor on a subset of rat natural killer cells.

Authors:  Christine L Hsieh; Kazuhito Nagasaki; Olivia M Martinez; Sheri M Krams
Journal:  Eur J Immunol       Date:  2006-08       Impact factor: 5.532

4.  Msh6 protects mature B cells from lymphoma by preserving genomic stability.

Authors:  Jonathan U Peled; Rani S Sellers; Maria D Iglesias-Ussel; Dong-Mi Shin; Cristina Montagna; Chunfang Zhao; Ziqiang Li; Winfried Edelmann; Herbert C Morse; Matthew D Scharff
Journal:  Am J Pathol       Date:  2010-10-07       Impact factor: 4.307

5.  Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model.

Authors:  Jose M Ayuso; Regan Truttschel; Max M Gong; Mouhita Humayun; Maria Virumbrales-Munoz; Ross Vitek; Mildred Felder; Stephen D Gillies; Paul Sondel; Kari B Wisinski; Manish Patankar; David J Beebe; Melissa C Skala
Journal:  Oncoimmunology       Date:  2018-12-12       Impact factor: 8.110

6.  TYK2 is a key regulator of the surveillance of B lymphoid tumors.

Authors:  Dagmar Stoiber; Boris Kovacic; Christian Schuster; Carola Schellack; Marina Karaghiosoff; Rita Kreibich; Eva Weisz; Michaela Artwohl; Olaf C Kleine; Mathias Muller; Sabina Baumgartner-Parzer; Jacques Ghysdael; Michael Freissmuth; Veronika Sexl
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

7.  Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.

Authors:  Hideyuki Nakashima; Toshio Fujisawa; Syed R Husain; Raj K Puri
Journal:  J Transl Med       Date:  2010-11-10       Impact factor: 5.531

8.  Dysregulation of CXCR3 signaling due to CXCL10 deficiency impairs the antiviral response to herpes simplex virus 1 infection.

Authors:  Todd R Wuest; Daniel J J Carr
Journal:  J Immunol       Date:  2008-12-01       Impact factor: 5.422

9.  A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models.

Authors:  Hideyuki Nakashima; Masaki Terabe; Jay A Berzofsky; Syed R Husain; Raj K Puri
Journal:  J Immunol       Date:  2011-10-17       Impact factor: 5.426

10.  Interplay between the heterotrimeric G-protein subunits Galphaq and Galphai2 sets the threshold for chemotaxis and TCR activation.

Authors:  Jacob Ngai; Marit Inngjerdingen; Torunn Berge; Kjetil Taskén
Journal:  BMC Immunol       Date:  2009-05-08       Impact factor: 3.615

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.